Rationale and design of the Anti-Xa Therapy to Lower cardiovascular events in Addition to standard therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS-ACS 2 TIMI 51) trial: A randomized, double-blind, placebocontrolled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome - Gibson, CM; Mega, JL; Burton, P (Am Heart J, 2011)
et al.